Shawarma Restaurant in Cairo Brings Taste of Home for Displaced Palestinians

General view of buildings by the Nile River in Cairo, Egypt. Reuters file photo
General view of buildings by the Nile River in Cairo, Egypt. Reuters file photo
TT

Shawarma Restaurant in Cairo Brings Taste of Home for Displaced Palestinians

General view of buildings by the Nile River in Cairo, Egypt. Reuters file photo
General view of buildings by the Nile River in Cairo, Egypt. Reuters file photo

A Palestinian businessman displaced by the war in Gaza is bringing a taste of home for fellow refugees with a Shawarma restaurant he has opened in Cairo, Reuters reported.
"The Restaurant of Rimal Neighborhood" offers Shawarma, a Middle Eastern dish of thinly-sliced meat, and other Palestinian and Arab dishes.
"The name comes to eternalize Rimal, my neighborhood, and to eternalize my homeland too," said Basem Abu Al-Awn.
"It is also to replace the restaurant I once had in Gaza. Two restaurants of mine, in addition to my house and the houses of my relatives, were destroyed," he said.
Abu Al-Awn hopes his time outside Gaza will be temporary and he is determined to return to the enclave once the war between Israel and Hamas is over.
"I will return, even if I have to set up a tent near the rubble of my house. We are going back to Gaza and we will rebuild it," he told Reuters.
Rimal was Gaza City's busiest shopping center, with large malls and main bank offices before Israeli forces reduced most of it to rubble. It was also home to Gaza's most famous Shawarma places.
"The taste is the same, people tell us it tastes as if they are eating it in Gaza," said Ahmed Awad, the new restaurant's manager.
"The Egyptians who get to try our place keep coming back. They tell us the taste is nice and is different from the Shawarma they usually get," Awad said.
Gaza Shawarma spices are unique and scarce in Cairo, so credit goes to Awad's father, who mixes those available to give the dish a special Palestinian taste.
Many thousands of Palestinians have arrived in Gaza since the war began last October.

Awad, his wife, and four children arrived in Cairo three months ago. In Gaza, he used to work in restaurants specializing in oriental and Western dishes.
With an end to the war looking like a distant prospect, Awad urged Palestinians not to give up.
"I advise them to work, and take care of their lives, their houses and everything may have gone but no problem, it will come back again," he said. "Once things are resolved we will return home, work there, and rebuild our country."
Palestinians now stranded in Cairo include businessmen, students and ordinary families who say they seek some kind of temporary legal residency to pursue investment and study plans until a ceasefire is in place.
Palestinian and Egyptian leaders reject the permanent settlement of Palestinians outside their land.
Om Moaz, from Rafah in the southern Gaza Strip, had been struggling to pay for a rented house and treatment for her husband and daughter in Cairo. She began working from home, offering Palestinian food through social media.
She found there was a strong demand from both Egyptians and Palestinians.
"Some were in the war and came to Egypt. So they started ordering my food. And thank God, it's a successful business and hopefully, it continues," she said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”